ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Reduction in gefitinib resistance mediated by Yi-Fei San-Jie pill in non-small cell lung cancer through regulation of tyrosine metabolism, cell cycle, and the MET/EGFR signaling pathway

Yang, Cai-Zhi; Guo, Wei; Wang, Yi-Fan; Hu, Lei-Hao; Wang, Jing; Luo, Jia-Min; Yao, Xiao-Hui; Liu, Shan; Tao, Lan-Ting; Sun, Ling-Ling*; Lin, Li-Zhu*广东省人民医院; 广州中医药大学; 1
Journal of Ethnopharmacology2023-10-5DOI: 10.1016/j.jep.2023.116566
2被引18阅读
引用收藏
分享

摘要

Ethnopharmacological relevance: The Chinese herbal prescription Yi-Fei San-Jie pill (YFSJ) has been used for adjuvant treatment in patients with lung cancer for a long time. Aim of the study: Reports have indicated that the combination of gefitinib (Gef) with YFSJ inhibits the proliferation of EGFR-TKI-resistant cell lines by enhancing cellular apoptosis and autophagy in non-small cell lung cancer (NSCLC). However, the molecular mechanisms underlying the effect of YFSJ on EGFR-TKI resistance and related metabolic pathways remain to be explored. Materials and methods: In our report, ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), metabolomics, network pharmacology, bioinformatics, and biological analysis methods were used to investigate the mechanism. Results: The UPLC-MS/MS data identified 42 active compounds of YFSJ extracts. YFSJ extracts can enhance the antitumor efficacy of Gef without hepatic and renal toxicity in vivo. The analysis of the metabolomics pathway enrichment revealed that YFSJ mainly affected the tyrosine metabolism pathway in rat models. Moreover, YFSJ has been shown to reverse Gef resistance and improve the effects of Gef on the cellular viability, migration capacity, and cell cycle arrest of NSCLC cell lines with EGFR mutations. The results of network pharmacology and molecular docking analyses revealed that tyrosine metabolism-related active compounds of YFSJ affect EGFRTKIs resistance in NSCLC by targeting cell cycle and the MET/EGFR signaling pathway; these findings were validated by western blotting and immunohistochemistry. Conclusions: YFSJ inhibits NSCLC by inducing cell cycle arrest in the G1/S phase to suppress tumor growth, cell viability, and cell migration through synergistic effects with Gef via the tyrosine metabolic pathway and the EGFR/MET signaling pathway. To summarize, the findings of the current study indicate that YFSJ is a prospective complementary treatment for Gef-resistant NSCLC.

学科与关键词

关键词
Non-small cell lung cancerYi-Fei San-Jie pillGefitinib resistanceTyrosine metabolismNetwork pharmacologyCell cycle
相关
加载中…
  • A Mechanism Exploration for the Yi-Fei-San-Jie Formula against Non-Small-Cell Lung Cancer Based on UPLC-MS/MS, Network Pharmacology, and In Silico Verification
    Hu, Leihao; He, Canfeng; Mo, Aier; Zhan, Xingkai; Yang, Caizhi; Guo, Wei; Sun, Lingling; Su, Weiwei*; Lin, Lizhu*Evidence-based Complementary and Alternative Medicine, 2023, 2023: 3436814.被引 1
  • Deciphering the Effects and Mechanisms of Yi-Fei-San-Jie-pill on Non-Small Cell Lung Cancer With Integrating Network Target Analysis and Experimental Validation
    Yang, Hongxing; Guo, Qiuyan; Wu, Jianbin; Zhong, Lixia; Sun, Lingling; Liu, Wei; Wang, Jigang*; Lin, Lizhu*Frontiers in Pharmacology, 2022, 13: 851554.被引 2
  • Identification of the active compounds in the Yi-Fei-San-Jie formula using a comprehensive strategy based on cell extraction/UPLC-MS/MS, network pharmacology, and molecular biology techniques
    Hu, Leihao; Luo, Jiamin; Wen, Guiqing; Sun, Lingling; Liu, Wei; Hu, Hao; Li, Jing; Wang, Lisheng*; Su, Weiwei*; Lin, Lizhu*PHYTOMEDICINE, 2023, 115: 154843.
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Ethnopharmacology
发表日期
2023-10-05
卷期
第 314 卷
页码
116566
DOI
10.1016/j.jep.2023.116566
语言
ENGLISH
成果收录
SCIE
资助标注
Collaborative Innovation Research and High-Level Team Building of Integrated Chinese and Western Medicine in Diagnosis and Treatment of Malignant Tumors [2021XK09]; National Natural Science Foundation of China [[2022]-7]; Basic Theoretical Research of Chinese Medicine of the Guangzhou University of Chinese Medicine; Cooperative Research of High-Level Hospital Project (Lung Cancer) (2019-2022); [82104647]; [81973775]

作者

  • Y

    Yang, Cai-Zhi (第一作者)

    1 · guangzhou univ chinese med

  • G

    Guo, Wei

    1 · guangzhou univ chinese med

查看全部 11 位作者收起作者
  • W

    Wang, Yi-Fan

    1 · guangzhou univ chinese med

  • H

    Hu, Lei-Hao

    1 · guangzhou univ chinese med

  • W

    Wang, Jing

  • L

    Luo, Jia-Min

    1 · guangzhou univ chinese med

  • Y

    Yao, Xiao-Hui

    guangzhou univ chinese med

  • L

    Liu, Shan

    1 · guangzhou univ chinese med

  • T

    Tao, Lan-Ting

  • S

    Sun, Ling-Ling (通讯)

    1 · guangzhou univ chinese med · guangdong prov hosp

  • L

    Lin, Li-Zhu (通讯)

    1 · guangzhou univ chinese med · guangdong prov hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417